The existence of homozygous insertional polymorphisms of the SMARCA2 promoter, located −741 bp and −1321 bp from the transcription start site, has previously been linked to loss of SMARCA2 expression in lung cancer [26]. Here, SMARCA2 is linked to lung carcinoma.